BioCardia to Host Corporate Update for Q2 2025
BioCardia, Inc. (NASDAQ: BCDA), a pioneer in developing advanced cellular and cell-derived therapies for cardiovascular and pulmonary diseases, has made an exciting announcement. The company is set to provide a comprehensive corporate update and disclose its financial results for the three-month period ending June 30, 2025. This will take place via a conference call on August 11, 2025, at 4:30 PM ET. The call will follow a traditional format, beginning with formal remarks from the management team before opening the floor for a question-and-answer session, creating an interactive platform for stakeholders to engage with BioCardia's executive team.
How to Register for the Conference Call
Registration for this important event is straightforward. Interested participants can secure their spot by visiting the registration page. Once registered, participants will receive a unique dial-in number, ensuring seamless access to the call. Those who have not registered can still join the conference call by calling in approximately 10 minutes ahead of the start time. For U.S. callers, the number is 1-833-316-0559, while international participants can reach the call at 1-412-317-5730.
About BioCardia's Cell Therapeutics
BioCardia's innovative approach to treating serious cardiovascular conditions involves a blend of breakthrough technologies and extensive clinical experience. The CardiAMP® and CardiALLO™ cell therapies represent their flagship biotherapeutic platforms, currently in clinical development. These approaches aim to harness the healing potential of cellular therapies, addressing significant gaps in available treatments for ischemic heart diseases and pulmonary conditions.
Key Highlights of Their Clinical Developments
BioCardia is actively working on several clinical product candidates. Their therapies utilize cutting-edge methods for delivering cells directly to the damaged tissues, significantly improving the therapeutic outcome for patients. The Helix biotherapeutic delivery system and the Morph® vascular navigation technology are crucial components facilitating this advanced delivery mechanism, showcasing BioCardia's commitment to innovation in medical therapeutics.
Upcoming Webcast and Replay Availability
For those unable to attend the live call, a webcast replay will be readily available. Listeners can expect access approximately one hour after the call ends, providing a convenient way to catch up on the key announcements and insights shared during the conference. Additionally, all participants will have access to a telephonic replay of the call, allowing for further review of the discussions.
Contact Information for Further Inquiries
Should you have any questions or require more information regarding BioCardia’s initiatives or the upcoming conference call, feel free to reach out to their dedicated marketing and investor relations team. Miranda Peto is available at (650) 226-0120 for inquiries, while investors can contact Chief Financial Officer David McClung at the same number.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call aims to provide stakeholders with an update on BioCardia's corporate activities and to disclose financial results for the recent quarter.
How can I participate in the conference call?
Participants can register online to receive a unique dial-in number or call in directly using the numbers provided in the announcement.
What are BioCardia's main products?
BioCardia's primary products include the CardiAMP® and CardiALLO™ cell therapies, designed for treating cardiovascular and pulmonary diseases through innovative delivery techniques.
Will there be a replay available for the conference call?
Yes, both a webcast and telephonic replay will be available shortly after the call, allowing participants to review the information shared.
Who can I contact for investor relations inquiries?
You can contact Miranda Peto for marketing inquiries or David McClung for investor-related questions at (650) 226-0120.
